Crane Biosciences
Entrepreneur First '22Berlin, DE · Founded 2022 · 2 known investors
Crane Biosciences develops nanoparticles derived from red blood cells to carry nucleic acid therapeutics such as mRNA into the brain. The approach is intended to move these payloads across the blood-brain barrier without invasive administration. The company's focus is on treatments for neurological conditions.
Also known as Crane Biosciences
Founders & leadership
Crane Biosciences was founded in 2022 by Luca Bolondi and Sujaan Das.
Investors · 2
Also in the syndicate · 1
Company profile
researched Aug 2026Crane Biosciences is a biotechnology company working on drug delivery based on nanoparticles derived from red blood cells. The platform is designed to carry nucleic acid payloads, including mRNA, across the blood-brain barrier without invasive administration, with an application focus on neurological disease. Public descriptions of the company characterise the technology as red blood cell-derived nanoparticles for immune-evasive gene therapies with precise targeting and minimal side effects.
The company was founded in 2022 through the Entrepreneurs First talent-investor programme and is led by Luca Bolondi (CEO) and Sujaan Das (CTO). Public data on the company is thin: an ecosystem database lists a Delaware, United States headquarters location and reports no known external funding, while a separate funding database records an initial investment by Entrepreneur First Investment Manager LLP with the transaction amount not disclosed.
Founding story
The company was formed via Entrepreneurs First, an incubator that invests in individuals pre-team and pre-idea and which is recorded as making the initial investment in Crane Biosciences.
Traction
Available public sources report no known external funding and provide no disclosed commercial, clinical or headcount metrics.
▸Full profile — technology, geography
Technology
Nanoparticles derived from red blood cells used as carriers for nucleic acid therapeutics, positioned publicly as enabling immune-evasive gene therapies with precise targeting and reduced side effects, and intended to cross the blood-brain barrier non-invasively.
Geography
A Berlin ecosystem database (sourced from Dealroom.co) lists the company's headquarters as Delaware, United States, and identifies its website as cranebio.com; the company also appears in the Berlin-region startup mapping.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsA database entry for Crane Biosciences records an initial investment by Entrepreneur First Investment Manager LLP (United Kingdom), a technology incubator that invests in individuals pre-team and pre-idea. The transaction amount and round label are listed as N/A.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Crane Biosciences | Portfolio | Entrepreneurs Firstjoinef.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Crane Biosciences do?
- Crane Biosciences develops red blood cell-derived nanoparticles to deliver nucleic acid therapeutics such as mRNA to the brain.
- Who founded Crane Biosciences?
- Crane Biosciences was founded by Luca Bolondi, Sujaan Das in 2022.
- Who are Crane Biosciences's investors?
- Crane Biosciences's investors include Entrepreneur First.
- Where is Crane Biosciences headquartered?
- Crane Biosciences is headquartered in Berlin, DE.